Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Grazoprevir + Elbasvir in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients
2016-001536-36Phase 3Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of grazoprevir in hepatitis C virus infection, chronic hepatitis C (CHC) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Primary efficacy - HCV viral load post-treatment. Started Jul 2016; status: active.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infectionchronic hepatitis C (CHC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-001536-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001536-36.